Myasthenia gravis market to reach $13.0bn across 7MM by 2034
MG treatment regimens are determined through the classification of a patient’s clinical status and autoantibody status.
Comment & Opinion
BMS Texas investment advances pharma’s modular manufacturing agenda
CKD market expected to reach $10.9bn across the 7MM by 2035
Intismeran autogene a turning point for cancer vaccines
Reformed pharmaceutical regulation across India’s drug landscape
Updated UK guidance for finerenone introduces new treatment for HF patients
Repligen’s deal for BioLife Solutions indicates shift to manufacturing integration
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
